BARD1 releases further positive results

Published at Mar 6, 2018, in Biotech

BARD1 Life Sciences (ASX:BD1) has announced additional positive results from its BARD1-Ovarian test, indicating that the test returned 89% sensitivity and 82% specificity.

BD1 conducted the follow on OC-400V study to assess the effectiveness of its ovarian algorithm generated in the OC-400 study to detect ovarian cancer in an independent test of 82 new ovarian cancers and 27 previously tested healthy controls.

The results of the OC-400V study (as indicated below) are highly promising and showcase high accuracy for detection of ovarian cancer. The results are an improvement over those recorded in the OC-400 study of 82% sensitivity and 79% specificity in cross validation tests.

bard1 life sciences ovarian cancer detection

Thanks to the results, BD1 confirmed the promise of its algorithm and now believes that BARD1-Ovarian has the potential to become a key diagnostic aid for early detection of the cancer.

It should be noted, however, that this is an early stage company and success is no guarantee. Investors should seek professional financial advice before making an investment.

BD1 Executive Director and CSO Dr Irmgard Irminger-Finger spoke on the promising results, “This study provides further evidence of the robustness of the BARD1-Ovarian test.

“Upon transfer to a commercial platform, our ongoing product development efforts will focus on testing BARD1-Ovarian in larger sample sets and the addition of other immunogenic markers to our biomarker panel to further train the algorithm and increase its accuracy for early detection of ovarian cancer.”

BD1 CEO Leearne Hinch also informed the market that the company was in discussions with a number of contract laboratory organisations that could transfer its research essay to a commercial platform.

“BARD1 anticipates that transfer of our research assay to a commercial platform will enable more efficient development and commercialisation of our diagnostic pipeline for detection of lung, ovarian and other cancers,” she said.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Thanks for subscribing!